Home Meeting Coverage ASH Annual Meeting ASH Annual MeetingMeeting CoverageMultimedia Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology Tuesday, March 7, 2017 Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies. Advertisement Recent Articles Editor’s Corner: A Period Piece Tuesday, January 19, 2021 It happens every week in my clinic. I ask a patient one simple question and the floodgates open. I hear confessions of days upon... Bethany T. Samuelson Bannow, MD Tuesday, January 19, 2021 Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms Friday, January 15, 2021 Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings... FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia Friday, January 15, 2021 Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia... Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection Friday, January 15, 2021 Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people... Current Issue Mid-January 2021 Annual Meeting Edition Friday, January 15, 2021 This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.